Hemostemix Inc (OTC: HMTXF) (TSXV: HEM) Announces Closure of Unit Private Placement

Highlights:

·         The company has announced the closing of the first tranche of its non-brokered private placement of units for gross proceeds of $690K. Each unit contains one common share in the capital of the company and one common share purchase warrant.

·         Hemostemix Inc recently announced that it has incorporated PreCerv Inc. as a wholly owned subsidiary. PreCerv will get the license to use NCP-01 and its autologous stem cell technologies, to treat conditions of the central and peripheral nervous system.

·         Hemostemix Inc. has appointed Mr. Peter Pavlin to the position of Vice President Operations for the company.  He was a consultant to Vadeko International, applied state of the art real time tracking technology, evaluating the performance of the NASA Space Shuttle ASRM.

Hemostemix Inc (OTC: HMTXF) (TSX-V: HEM) is a Canada based publicly-traded autologous stem cell therapy company. The company has published seven peer reviewed articles about the safety and efficiency of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of the disease.

Three years back, Hemostemix announced the results of its phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No revascularization options”. The result described that healing of ulcers and resolution of ischemic rest pain occurred in 83%of patients.

Also read: 

Hemostemix’s Intellectual property is back home 

https://finance.yahoo.com/news/hemostemix-announces-intellectual-property-back-130000091.html

Details about the closure of Unit Private Placement:

The non-brokered private placement of units consisted of the issuance of an aggregate of 2,301,296 Units at a price of $0.30 per unit. Every unit consists of one common share in the capital of the company and one common share purchase warrant.

Each full warrant has been authorized to the holders to acquire one common share at a price of $0.55 per common share for a time period of 24 months from the closing of the offer.  The company paid eligible finders aggregate cash finder fees of $23,915.90 and issued almost 80,000 finder’s options to purchase common shares of the company.

Company’s Financial:

Hemostemix Inc., a Canada based company listed in OTC as HMTXF and TSX-V as HEM has an overall stock float of $58.34M. From the total, 14.71% stock is held by the insiders and other by the public.

All of the financial statements are for the most current period, according to the SEC filing. The proposed offering's joint book-runners are The Benchmark Company, LLC and HCFP/Capital Markets LLC.

Conclusion:

Attractive Valuation of 58.34Million, Niche focused on biotechnology and successful trials deliver a strong likelihood of Hemostemix Inc. being an attractive investment. Ongoing year’s surge of biotechnological invention, emphasizes gradual increase in investor’s confidence in the economy. Investors praised the recent offering made by the company. Hemostemix Inc’s specialized approach, according to analysts, is expected to attract more investors and could be great revenue generator in the upcoming months.